Specialized lipid nanoparticle formulation and delivery development for antisense oligonucleotides.
Antisense oligonucleotides (ASOs) offer highly sequence-specific modulation of RNA biology, but their therapeutic potential is often limited by inefficient cellular uptake, endosomal retention, nuclease exposure, poor tissue selectivity, and formulation-dependent activity loss. For drug discovery teams working with gapmers, steric-blocking ASOs, splice-switching oligonucleotides, or chemically modified ASO candidates, a delivery system must do more than encapsulate the sequence—it must preserve oligonucleotide integrity, control particle architecture, support productive intracellular trafficking, and generate interpretable performance data across formulation iterations. BOC Sciences provides lipid nanoparticle (LNP) development services for ASO delivery, integrating lipid composition design, microfluidic formulation, encapsulation optimization, physicochemical characterization, release profiling, and cellular evaluation to help researchers identify delivery systems matched to ASO chemistry, target cell type, and project objectives.
ASO loaded lipid nanoparticle structureWe develop ASO-loaded LNP systems through a formulation-first and data-driven workflow. Each service module is designed to address the practical questions commonly faced by pharmaceutical and biotechnology teams: how to load the ASO efficiently, how to maintain nanoparticle stability, how to reduce non-productive uptake, and how to select a formulation with measurable intracellular activity.
We design lipid nanoparticle systems around the physicochemical properties of the ASO sequence, including length, backbone chemistry, phosphorothioate content, charge density, hydrophobic modifications, and intended target cell type.
Efficient ASO loading requires precise control of electrostatic interactions between negatively charged oligonucleotides and ionizable lipid components. We optimize formulation conditions to achieve stable association without compromising release potential.
Reproducible mixing is essential for ASO-LNP development because particle formation occurs rapidly during lipid and aqueous phase contact. Our microfluidic LNP production services enable controlled formulation screening with tunable process parameters.
ASO delivery performance is highly dependent on lipid selection. We optimize lipid components to improve endosomal interaction, intracellular release, and formulation stability while maintaining compatibility with the oligonucleotide cargo.
We provide a comprehensive analytical package to define the physical and chemical attributes of ASO-loaded nanoparticles. This service can be integrated with broader lipid nanoparticle characterization workflows.
A successful ASO-LNP formulation should demonstrate not only uptake but also functional delivery to the intracellular compartment where the ASO can engage its RNA target. We design in vitro evaluation strategies around the ASO mechanism and cell model.
ASO delivery differs from mRNA or siRNA delivery because ASOs vary widely in chemical modification, length, binding mechanism, and intracellular site of action. BOC Sciences applies formulation strategies that consider both LNP assembly behavior and ASO pharmacological function.
From lipid composition screening to cellular activity evaluation, BOC Sciences helps research teams transform ASO delivery questions into structured formulation data.
Different ASO classes require different LNP design priorities. Some projects emphasize high encapsulation and protection, while others require improved intracellular trafficking, nuclear access, or target-cell selectivity. Our ASO-LNP services are customized according to sequence chemistry, mechanism of action, and biological evaluation strategy.
| ASO Cargo or Project Type | Formulation Focus and Evaluation Strategy |
|---|---|
| RNase H Gapmer ASOs | LNP development for cytosolic and nuclear availability, target mRNA reduction, ASO integrity, and reduced non-productive lysosomal accumulation. |
| Splice-Switching ASOs | Formulation screening focused on cellular uptake, nuclear delivery, exon modulation readouts, and sequence-dependent formulation compatibility. |
| Steric-Blocking ASOs | Optimization of lipid composition and release behavior to support target binding without requiring RNase H recruitment. |
| Phosphorothioate ASOs | Evaluation of lipid-ASO interactions, serum-associated stability, particle charge behavior, and free-versus-encapsulated ASO distribution. |
| Fluorescently Labeled ASOs | Useful for uptake, trafficking, intracellular localization, and endosomal escape studies in candidate formulation screening. |
| Targeted ASO-LNP Systems | Integration with targeted LNP development strategies, including surface ligand design and cell-type-focused uptake evaluation. |
| RNA Therapeutic Platform Comparisons | Comparative LNP formulation approaches for ASO projects alongside lipid nanoparticles for RNA delivery, siRNA, or mRNA delivery programs. |
ASO-LNP development often fails when formulation screening relies only on particle size or encapsulation efficiency. We address the delivery barriers that determine whether an ASO reaches its functional intracellular compartment.
✔ Low ASO Encapsulation Efficiency
Some ASO chemistries interact weakly or irregularly with lipid components. We screen ionizable lipid ratios, aqueous phase pH, ASO concentration, and mixing conditions to improve loading while preserving particle uniformity.
✔ High Uptake but Weak Functional Activity
Strong cellular uptake does not always indicate productive delivery. We combine uptake analysis with target RNA modulation and intracellular localization to identify formulations that support functional ASO release.
✔ Endosomal and Lysosomal Trapping
ASO cargo can accumulate in endosomal compartments without reaching the nucleus or cytosol. We adjust ionizable lipid behavior and helper lipid composition, then assess trafficking patterns with microscopy-based assays.
✔ Particle Instability After Buffer Exchange
ASO-LNPs may aggregate during dialysis, concentration, or storage buffer transfer. We optimize buffer composition, PEG-lipid percentage, ionic strength, and processing conditions to maintain colloidal stability.
✔ Sequence-Dependent Formulation Variability
ASOs with similar length may behave differently due to backbone chemistry, base composition, and hydrophobic modification. We build sequence-specific formulation matrices rather than applying a universal LNP recipe.
✔ Poor Correlation Between Loading and Activity
High encapsulation may coexist with poor intracellular release. We integrate LNP encapsulation efficiency optimization with functional assays to rank candidates by delivery performance, not loading alone.
We review ASO length, backbone chemistry, modification pattern, target RNA mechanism, intended cell model, and available analytical readouts to define formulation objectives.
We construct a lipid composition and process-parameter matrix covering ionizable lipid ratio, helper lipid selection, PEG-lipid content, pH, N/P ratio, and microfluidic mixing conditions.
Candidate ASO-LNPs are prepared and evaluated for size, PDI, zeta potential, encapsulation efficiency, ASO integrity, short-term stability, and formulation reproducibility.
Selected formulations are tested in relevant in vitro models for uptake, intracellular localization, target RNA modulation, and delivery-performance ranking.
Challenge: A discovery team developed a 16-mer phosphorothioate gapmer ASO targeting a liver-associated transcript. The ASO showed acceptable activity when transfected with a research reagent, but the first LNP formulation produced strong uptake signals in hepatocyte-like cells with less than 25% target mRNA reduction.
Diagnosis: Fluorescence microscopy showed that most labeled ASO signal remained in punctate vesicular structures after 24 hours. Encapsulation efficiency was above 85%, but the lipid composition favored stable ASO retention and limited release after endosomal uptake. The formulation therefore looked successful by loading data but underperformed in functional delivery.
Solution: BOC Sciences designed a 24-condition formulation matrix that varied ionizable lipid ratio, helper lipid composition, PEG-lipid percentage, and N/P ratio. Candidate LNPs were produced using controlled microfluidic mixing and screened for size below 120 nm, PDI below 0.20, ASO integrity, and encapsulation efficiency. The top eight formulations were then evaluated for uptake, endosomal co-localization, and target mRNA knockdown. A formulation with a moderately reduced PEG-lipid level and a membrane-active helper lipid profile achieved a better balance between colloidal stability and intracellular release.
Result: The optimized ASO-LNP maintained high encapsulation while improving target mRNA reduction from less than 25% to approximately 70% in the selected cell model. The client received a ranked formulation dataset linking lipid composition, particle attributes, intracellular localization, and functional activity.
Challenge: A biotechnology client required an LNP formulation for a splice-switching ASO intended to alter exon usage in a neuronal cell model. Early formulations showed acceptable particle size but inconsistent splice correction and gradual aggregation after buffer exchange.
Diagnosis: Size analysis revealed that several formulations shifted from approximately 90 nm to more than 180 nm after buffer exchange. Confocal imaging indicated that the ASO entered cells but remained largely trapped in late endosomal compartments. The ASO sequence also showed sensitivity to high ionic strength during post-formulation handling.
Solution: Our team adjusted the formulation workflow by lowering the ASO concentration during initial mixing, screening alternative ionizable lipid ratios, and modifying the buffer exchange strategy to reduce aggregation stress. We compared formulations under matched ASO dose conditions and selected candidates based on particle stability, free ASO level, nuclear-associated fluorescence, and exon-modulation readout. Additional PEG-lipid tuning was performed to prevent aggregation without excessively reducing cell interaction.
Result: The final candidate maintained particle size below 110 nm after buffer exchange, reduced visible aggregation, and produced a clearer splice-switching signal compared with the starting formulation. The project demonstrated that process handling and intracellular trafficking data were both essential for selecting a practical ASO-LNP candidate.
ASO-Specific Formulation LogicWe do not treat ASOs as generic nucleic acid cargo. Our development strategy considers ASO length, backbone chemistry, mechanism of action, intracellular destination, and target-cell biology.
Integrated LNP Development PlatformOur services connect lipid nanoparticle formulation, preparation, characterization, encapsulation testing, and cellular evaluation into a coherent ASO delivery workflow.
Function-Oriented Candidate RankingWe rank ASO-LNP candidates using both analytical and biological readouts, helping teams avoid formulations that look strong by loading data but fail to produce meaningful intracellular activity.
Targeted Delivery ExpansionFor projects requiring cell- or tissue-focused delivery, we can integrate ligand display, surface engineering, and organ-oriented LNP design strategies, including liver-, lung-, tumor-, and brain-focused delivery exploration.
Advanced Troubleshooting CapabilityWhen ASO-LNP projects encounter poor activity, aggregation, low encapsulation, or inconsistent uptake, our LNP transfection troubleshooting services help identify formulation and process variables that limit performance.
Lipid nanoparticles for ASO delivery are designed to address several major limitations of naked antisense oligonucleotides, including poor membrane permeability, nuclease sensitivity, rapid clearance, and limited cellular uptake. Because ASOs are highly hydrophilic and negatively charged, they often require a delivery platform that can condense, protect, and transport them into target cells. LNPs provide a tunable lipid-based architecture in which ionizable lipids interact with ASOs during formulation, while helper lipids, cholesterol, and PEG-lipids support particle stability, size control, and colloidal behavior. For drug development teams, LNPs are valuable not only as carriers but also as formulation tools that allow systematic optimization of encapsulation efficiency, particle size, cellular uptake, endosomal escape, and intracellular ASO activity.
The performance of lipid nanoparticles for ASO delivery is influenced by both formulation composition and process parameters. Key variables include ionizable lipid structure, helper phospholipid ratio, cholesterol content, PEG-lipid percentage, ASO-to-lipid ratio, N/P ratio, buffer pH, mixing speed, total lipid concentration, and ASO concentration. A formulation with high encapsulation efficiency may still show weak biological activity if it has poor endosomal escape or unstable intracellular release. Similarly, a small and uniform particle size may improve dispersion but does not automatically guarantee effective ASO delivery. Therefore, ASO-LNP development should evaluate physicochemical properties together with functional endpoints, such as cellular uptake, target RNA modulation, cytotoxicity profile, and serum stability. BOC Sciences can support formulation screening by comparing multiple lipid compositions and preparation conditions to identify delivery systems with balanced stability and biological performance.
ASO encapsulation in lipid nanoparticles is typically evaluated by distinguishing encapsulated or lipid-associated ASO from free ASO in the aqueous phase. This can be achieved through dye-accessibility assays, ultrafiltration, size-exclusion chromatography, nuclease protection assays, or quantitative analysis before and after nanoparticle disruption. For ASO-LNP systems, direct UV absorbance at 260 nm may be unreliable because lipid components, particle scattering, and buffer background can interfere with the signal. A more robust approach involves measuring the ASO signal in intact particles and then after complete LNP lysis, allowing calculation of free ASO, encapsulated ASO, total recovery, and encapsulation efficiency. BOC Sciences can develop fit-for-purpose analytical workflows based on ASO length, chemical modification, labeling strategy, and lipid composition, helping clients avoid misleading data caused by incomplete lysis, dye quenching, or matrix interference.
Lipid nanoparticles for ASO delivery may fail for reasons that are not directly related to ASO sequence potency. A common issue is inefficient intracellular release. LNPs can promote cellular uptake, but if most particles remain trapped in endosomes or are routed toward lysosomal degradation, only a small fraction of ASO reaches the intracellular site required for target engagement. Other causes include unstable ASO-lipid complexation, particle aggregation in biological media, excessive PEG shielding, suboptimal ionizable lipid pKa, low serum stability, or poor compatibility with the selected cell model. In some projects, fluorescence imaging may show strong particle uptake while target RNA modulation remains weak, indicating that internalization alone is insufficient. Effective troubleshooting should combine particle characterization, ASO integrity testing, uptake studies, endosomal escape assessment, and functional target knockdown analysis to identify which step limits delivery performance.
To start a lipid nanoparticles for ASO delivery project, clients should provide as much information as possible about the ASO and the intended research application. Useful details include ASO sequence length, molecular weight, chemical modifications, charge characteristics, fluorescent labeling status, target cell type, desired biological readout, and any existing delivery challenges. If an LNP formulation has already been attempted, information about lipid composition, molar ratio, N/P ratio, buffer system, mixing method, particle size, PDI, encapsulation efficiency, and storage behavior can help accelerate troubleshooting. For early-stage projects, BOC Sciences can support exploratory formulation development by screening different ionizable lipid ratios, helper lipid combinations, PEG-lipid levels, and preparation parameters. This stepwise strategy helps identify the formulation variables that most strongly affect ASO loading, nanoparticle stability, cellular uptake, and in vitro activity, reducing unnecessary trial-and-error during development.
